Dabrafenib showed a ORR of 32% in 78 patients with BRAF-mutated NSCLC; 2-stage phase II study with the second phase evaluating the combination of MEK inhibitor trametinib and dabrafenib is ongoing. Here, BRAF is linked to non-small cell lung carcinoma.